Centiva Capital LP Sells 7,614 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Centiva Capital LP lowered its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 60.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,977 shares of the medical equipment provider's stock after selling 7,614 shares during the period. Centiva Capital LP's holdings in Zimmer Biomet were worth $537,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the business. American Century Companies Inc. grew its position in shares of Zimmer Biomet by 12.6% during the 2nd quarter. American Century Companies Inc. now owns 6,463,845 shares of the medical equipment provider's stock valued at $701,521,000 after purchasing an additional 722,041 shares in the last quarter. Van ECK Associates Corp boosted its position in shares of Zimmer Biomet by 12.4% during the 3rd quarter. Van ECK Associates Corp now owns 3,736,761 shares of the medical equipment provider's stock valued at $391,239,000 after acquiring an additional 411,163 shares during the last quarter. Victory Capital Management Inc. grew its holdings in shares of Zimmer Biomet by 6.7% during the second quarter. Victory Capital Management Inc. now owns 3,364,624 shares of the medical equipment provider's stock worth $365,163,000 after purchasing an additional 211,637 shares in the last quarter. Allspring Global Investments Holdings LLC increased its position in shares of Zimmer Biomet by 0.4% in the third quarter. Allspring Global Investments Holdings LLC now owns 2,569,311 shares of the medical equipment provider's stock worth $277,357,000 after purchasing an additional 9,990 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in Zimmer Biomet by 9.3% in the second quarter. Dimensional Fund Advisors LP now owns 1,810,770 shares of the medical equipment provider's stock valued at $196,523,000 after purchasing an additional 154,447 shares in the last quarter. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Zimmer Biomet Trading Down 1.0 %

ZBH stock traded down $1.13 during trading on Friday, reaching $108.03. The company had a trading volume of 1,141,079 shares, compared to its average volume of 1,403,075. The company has a market cap of $21.51 billion, a P/E ratio of 20.54, a PEG ratio of 1.99 and a beta of 1.02. The business has a 50 day moving average of $107.52 and a 200 day moving average of $108.95. Zimmer Biomet Holdings, Inc. has a 52 week low of $101.47 and a 52 week high of $133.90. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.36 and a quick ratio of 0.70.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its quarterly earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, hitting analysts' consensus estimates of $1.74. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The firm had revenue of $1.82 billion for the quarter, compared to analysts' expectations of $1.80 billion. During the same period in the previous year, the firm posted $1.65 EPS. The business's revenue for the quarter was up 4.1% compared to the same quarter last year. As a group, sell-side analysts forecast that Zimmer Biomet Holdings, Inc. will post 7.99 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. Evercore ISI lowered their price objective on shares of Zimmer Biomet from $113.00 to $110.00 and set an "in-line" rating on the stock in a research report on Tuesday, October 1st. Royal Bank of Canada upped their price objective on Zimmer Biomet from $120.00 to $125.00 and gave the stock an "outperform" rating in a report on Monday, November 4th. TD Cowen decreased their price target on shares of Zimmer Biomet from $143.00 to $119.00 and set a "hold" rating on the stock in a research note on Friday, September 6th. Wolfe Research initiated coverage on shares of Zimmer Biomet in a research note on Tuesday, September 10th. They issued a "peer perform" rating for the company. Finally, BTIG Research decreased their target price on shares of Zimmer Biomet from $134.00 to $126.00 and set a "buy" rating on the stock in a research report on Thursday, October 3rd. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $123.22.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.